The recent tudriqev milestone marks an important development in oncology, as the U.S. FDA granted accelerated approval on August 6, 2026, to TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with nivolumab. The therapy is indicated for adults with unresectable advanced cutaneous melanoma whose disease progressed following an anti-PD-1 antibody-based regimen. The decision was based on...